The risk of seizures among the carbapenems: A meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2043-2055

  Cannon, Joan P ^a,e   Lee, Todd A ^b   Clark, Nina M ^c   Setlak, Paul ^d   Grim, Shellee A ^b,c  

^a HINES VA HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Doripenem; Epileptogenic; Ertapenem; Imipenem; Meropenem

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BIAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM; CILASTATIN; CILASTATIN, IMIPENEM DRUG COMBINATION; DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ARTICLE; ATTRIBUTABLE RISK; EPILEPTOGENESIS; HUMAN; META ANALYSIS (TOPIC); RISK ASSESSMENT; SEIZURE; SYSTEMATIC REVIEW; ADULT; CHEMICALLY INDUCED; CHILD; DRUG COMBINATION; META ANALYSIS; RISK; SEIZURES;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; CHILD; CILASTATIN; DRUG COMBINATIONS; HUMANS; IMIPENEM; RISK; SEIZURES; THIENAMYCINS;

EID: 84904577121     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku111     Document Type: Article

References (94)

1. Clark NM, Patterson J, Lynch JP 3rd. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 413-23.
2. Calandra GB, Brown KR, Grad LC et al. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med 1985; 78: 73-8.
3. Wong VK, Wright HT Jr, Ross LA et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122-5.
4. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000; 22: 191-4.
5. Miller AD, Ball AM, Bookstaver PB et al. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011; 31: 408-23.
6. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74: 420-34.
7. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90.
8. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
9. Primaxin [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2012.
10. Merrem [package insert]. Wilmington, DE: Astra Zeneca, 2010.
11. Invanz [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2012.
12. Doribax [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2007.
13. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group, 2001.
14. Bradburn MJ, Deeks JJ, Berlin JA et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
15. Bartoloni A, Strohmeyer M, Corti G et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drug Exp Clin Res 1999; 25: 243-52.
16. Basoli A, Meli EZ, Mazzocchi P et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29: 503-8.
17. Brismar B, Malmborg AS, Tunevall G et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35: 139-48.
18. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38: 523-37.
19. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21: 86-92.
20. Fabian TC, File TM, Embil JM et al. Meropenem versus imipenemcilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect 2005; 6: 269-82.
21. Garau J, Blanquer J, Cobo L et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16: 789-96.
22. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intraabdominal infections requiring surgery. Meropenem Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 191-205.
23. Hamacher J, Vogel F, Lichey J et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients-a comparison of meropenem and imipenem/cilastatin. COPD Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 121-33.
24. Hou F, Li J, Wu G et al. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Chinese Med J (Engl) 2002; 115: 1849-54.
25. Kanellakopoulou K, Giamarellou H, Papadothomakos P et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12: 449-53.
26. Kuo BI, Fung CP, Liu CY. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Chin Med J 2000; 63: 361-7.
27. Lami JL, Wilson SE, Hopkins JA. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg 1991; 57: 769-74.
28. Maggioni P, Di Stefano F, Facchini V et al. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/ cilastatin. J Chemother 1998; 10: 114-21.
29. Nichols RL, Smith JW, Geckler RWet al. Meropenem versus imipenem/ cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995; 88: 397-404.
30. Romanelli G, Cravarezza P. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 109-19.
31. Romanelli G, Cravarezza P, Pozzi A et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother 2002; 14: 609-17.
32. Shah PM, Heller A, Fuhr HG et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996; 24: 480-4.
33. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6: 294-302.
34. Zanetti G, Harbarth SJ, Trampuz A et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 1999; 11: 107-13.
35. Hartenauer U, Kljucar S, Bender H-J et al. Meropenem versus imipenem/cilastatin for the treatment of serious bacterial infections at ICU. Antiinfect Drugs Chemother 1997; 15: 65-70.
36. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-96.
37. Kollef MH, Chastre J, Clavel M et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16: R218.
38. Brismar B, Akerlund JE, Sjostedt S et al. Biapenem versus imipenem/ cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish study group. Scand J Infect Dis 1996; 28: 507-12.
39. Jia B, Lu P, HuangWet al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy 2010; 56: 285-90.
40. Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intraabdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83.
41. Nakagawa Y, Suzuki K, Ohta K et al. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J Infect Chemother 2013; 19: 103-11.
42. Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-lifethreatening infections. German and Austrian Imipenem/Cilastatin Study Group. Eur J Clin Microbiol Infect Dis 1992; 11: 683-92.
43. Alvarez Lerma F. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13: 70-81.
44. Aoun M, Crokaert F, Paesmans M et al. Imipenem versus targeted therapy in cancer patients. Int J Antimicrob Agents 1998; 10: 263-70.
45. Aparicio J, Oltra A, Llorca C et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer 1996; 32A: 1739-43.
46. Bodey G, Abi-Said D, Rolston K et al. Imipenem or cefoperazonesulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996; 15: 625-34.
47. Calandra GB, Hesney M, Grad C. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol 1984; 3: 478-87.
48. Christou NV, Turgeon P, Wassef R et al. Management of intraabdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 1996; 131: 1193-201.
49. Feld R, DePauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-8.
50. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38: 547-57.
51. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
52. Gomis M, Barberan J, Sanchez B et al. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Rev Esp Quimioter 1999; 12: 244-9.
53. Gonik B. Postpartum endometritis: efficacy and tolerability of two antibiotic regimens. Clin Ther 1992; 14: 83-9.
54. Grayson ML, Gibbons GW, Habershaw GM et al. Use of ampicillin/ sulbactam versus imipenem/cilastatin in the treatment of limbthreatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-93.
55. Huizinga WK, Warren BL, Baker LWet al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995; 36 Suppl A: 179-89.
56. Jaccard C, Troillet N, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72.
57. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39: 1140-6.
58. Lode H, Wiley R, Hoffken G et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 1987; 31: 1491-6.
59. Marra F, Reynolds R, Stiver G et al. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998; 31: 355-68.
60. Mehtar S, Dewar EP, Leaper DJ et al. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997; 39: 631-8.
61. Miller JA, Butler T, Beveridge RA et al. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Clin Ther 1993; 15: 486-99.
62. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993; 31: 927-37.
63. Norrby SR, Vandercam B, Louie T et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis 1987; 52: 65-78.
64. Odio CM, Puig JR, Feris JM et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18: 581-90.
65. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34: 1076-83.
66. Raad II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039-47.
67. Raad II, Whimbey EE, Rolston KVet al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996; 77: 1386-94.
68. Rolston KV, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
69. Sieger B, Berman SJ, Geckler RW et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25: 1663-70.
70. Simpson AJ, Suputtamongkol Y, Smith MD et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29: 381-7.
71. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995; 36 Suppl A: 157-66.
72. Solomkin JS, Dellinger EP, Christou NV et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212: 581-91.
73. Solomkin JS, Fant WK, Rivera JO et al. Randomized trial of imipenem/ cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985; 78: 85-91.
74. Solomkin JS, Yellin AE, Rotstein OD et al. Ertapenem versus piperacillin/ tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235-45.
75. Vetter N, Cambronero-Hernandez E, Rohlf J et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 1770-85.
76. Winston DJ, Bartoni K, Bruckner DA et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998; 26: 576-83.
77. Winston DJ, Ho WG, Bruckner DA et al. b-Lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115: 849-59.
78. Winston DJ, Lazarus HM, Beveridge RA et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001; 32: 381-90.
79. Naber KG, Llorens L, Kaniga K et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53: 3782-92.
80. Namias N, Solomkin JS, Jensen EH et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 2007; 8: 15-28.
81. Rea-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-26.
82. Winston DJ, Ho WG, Bruckner DA et al. Controlled trials of double b-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 1988; 85: 21-30.
83. Berman SJ, Sieger B, Geckler RW et al. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. Curr Ther Res 1997; 58: 903-16.
84. Dincol D, Arican A, Aydin F et al. A comparison of imipenem monotherapy versus cefoperazone/sulbactam plus amikacin combination treatment in febrile neutropenic cancer patients. Cancer J 1998; 11: 89-93.
85. Schmutzhard E, Williams KJ, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 85-97.
86. Pomeroy SL, Holmes SJ, Dodge PR et al. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990; 323: 1651-7.
87. Zoons E, Weisfelt M, de Gans J et al. Seizures in adults with bacterial meningitis. Neurology 2008; 70: 2109-15.
88. Brismar B, Eklund AE, Nord CE. Immune response in patients with intra-abdominal infections treated with carbapenems. Int J Clin Pharmacol Res 1994; 14: 111-4.
89. Wang C, Calandra GB, Aziz MA et al. Efficacy and safety of imipenem/ cilastatin: a review of worldwide clinical experience. Rev Infect Dis 1985; 7 Suppl 3: S528-36.
90. Calandra G, Lydick E, Carrigan J et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911-8.
91. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007; 30: 657-68.
92. Teppler H, Gesser RM, Friedland IR et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53 Suppl 2: ii75-81.
93. Zhanel GG, Ketter N, Rubinstein E et al. Overview of seizure-inducing potential of doripenem. Drug Saf 2009; 32: 709-16.
94. Snydman D, Fink M, Niederman M et al. Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Drugs 1995; 49 Suppl 2: 439-41.